What are CDK9 inhibitor drugs?

CDK9 inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting CDK9). 0 are currently marketed, with 7 more in clinical development.

CDK9 inhibitor

0 marketed 1 in Phase 3 6 in Phase 2

This page covers all CDK9 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CDK9.

Targets

CDK9

Phase 3 pipeline (1)

RO4917838 · Hoffmann-La Roche · Oncology
RO4917838 is a small molecule that targets the CDK9 protein.

Phase 2 pipeline (6)

BAY2253651 · Bayer · Oncology
BAY2253651 is a small molecule that targets the CDK9 protein.
ASP0456 · Astellas Pharma Inc · Oncology
ASP0456 is a small molecule inhibitor of the CDK9 enzyme.
LY3832479 · Eli Lilly and Company · Oncology
LY3832479 is a small molecule that acts as a selective and potent inhibitor of the cyclin-dependent kinase 9 (CDK9).
CST-3056 · CuraSen Therapeutics, Inc. · Oncology
CST-3056 is a small molecule inhibitor of the CDK9 enzyme.
CAL02 · Eagle Pharmaceuticals, Inc. · Inflammation
CAL02 is a small molecule that targets the CDK9 enzyme, inhibiting its activity and thereby reducing the expression of inflammatory cytokines.
LY3838915 · Eli Lilly and Company · Oncology
LY3838915 is a small molecule that targets the CDK9 protein.